AC Immune Toekomstige groei
Future criteriumcontroles 5/6
De verwachting is dat AC Immune de winst en omzet met respectievelijk 54.7% en 32% per jaar zal laten groeien, terwijl de winst per aandeel naar verwachting zal groeien met 55.4% per jaar.
Belangrijke informatie
54.7%
Groei van de winst
55.4%
Groei van de winst per aandeel
Biotechs winstgroei | 28.3% |
Inkomstengroei | 32.0% |
Toekomstig rendement op eigen vermogen | n/a |
Dekking van analisten | Low |
Laatst bijgewerkt | 17 Nov 2024 |
Recente toekomstige groei-updates
Recent updates
AC Immune: Takeda Partnership Brings Funds To Drive Pipeline Forward
Jul 26AC Immune (NASDAQ:ACIU) Is In A Strong Position To Grow Its Business
Jun 15Shareholders Will Probably Hold Off On Increasing AC Immune SA's (NASDAQ:ACIU) CEO Compensation For The Time Being
Jun 15AC Immune SA's (NASDAQ:ACIU) 50% Share Price Surge Not Quite Adding Up
May 24AC Immune SA (NASDAQ:ACIU) May Have Run Too Fast Too Soon With Recent 30% Price Plummet
Apr 05We Think AC Immune (NASDAQ:ACIU) Can Afford To Drive Business Growth
Mar 15Companies Like AC Immune (NASDAQ:ACIU) Are In A Position To Invest In Growth
Oct 06We Think AC Immune (NASDAQ:ACIU) Can Afford To Drive Business Growth
Jun 03Will AC Immune (NASDAQ:ACIU) Spend Its Cash Wisely?
Nov 25AC Immune Non-GAAP EPS of -$0.23 in-line
Jul 28Here's Why We're Not Too Worried About AC Immune's (NASDAQ:ACIU) Cash Burn Situation
Jul 06AC Immune (NASDAQ:ACIU) Is In A Good Position To Deliver On Growth Plans
Feb 03AC Immune soars 17% on encouraging polyclonal antibody response in non-human primates
Jun 02Is AC Immune (NASDAQ:ACIU) In A Good Position To Deliver On Growth Plans?
May 09AC Immune reports Q1 results; outlook
Apr 28How Much Of AC Immune SA (NASDAQ:ACIU) Do Institutions Own?
Feb 28Analysts Just Made A Sizeable Upgrade To Their AC Immune SA (NASDAQ:ACIU) Forecasts
Jan 24We're Hopeful That AC Immune (NASDAQ:ACIU) Will Use Its Cash Wisely
Jan 19If You Had Bought AC Immune's (NASDAQ:ACIU) Shares Three Years Ago You Would Be Down 61%
Dec 15Need To Know: Analysts Are Much More Bullish On AC Immune SA (NASDAQ:ACIU) Revenues
Nov 19AC Immune EPS misses by CHF0.02, beats on revenue
Nov 13AC Immune and Wuxi Biologics boost development of TDP-43 antibodies
Nov 09AC Immune's Alzheimer's Setback, And Other News: The Good, Bad And Ugly Of Biopharma
Oct 30Winst- en omzetgroeiprognoses
Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
---|---|---|---|---|---|
12/31/2026 | 67 | -27 | 50 | -79 | 3 |
12/31/2025 | 62 | -23 | 25 | 28 | 4 |
12/31/2024 | 27 | -53 | -57 | 33 | 3 |
9/30/2024 | 41 | -40 | 43 | 44 | N/A |
6/30/2024 | 15 | -61 | 44 | 45 | N/A |
3/31/2024 | 15 | -55 | -43 | -43 | N/A |
12/31/2023 | 15 | -54 | -61 | -60 | N/A |
9/30/2023 | 0 | -68 | -62 | -62 | N/A |
6/30/2023 | 4 | -67 | -62 | -62 | N/A |
3/31/2023 | 4 | -69 | -68 | -67 | N/A |
12/31/2022 | 4 | -71 | -75 | -74 | N/A |
9/30/2022 | 4 | -73 | -76 | -74 | N/A |
6/30/2022 | N/A | -76 | -77 | -75 | N/A |
3/31/2022 | N/A | -75 | -74 | -71 | N/A |
12/31/2021 | N/A | -73 | -68 | -66 | N/A |
9/30/2021 | 1 | -71 | -70 | -67 | N/A |
6/30/2021 | 2 | -74 | -71 | -68 | N/A |
3/31/2021 | 3 | -71 | -69 | -67 | N/A |
12/31/2020 | 15 | -62 | -61 | -60 | N/A |
9/30/2020 | 15 | -62 | -54 | -53 | N/A |
6/30/2020 | 47 | -25 | -22 | -20 | N/A |
3/31/2020 | 48 | -26 | -22 | -20 | N/A |
12/31/2019 | 110 | 45 | 53 | 55 | N/A |
9/30/2019 | 111 | 50 | 55 | 56 | N/A |
6/30/2019 | 80 | 18 | 26 | 27 | N/A |
3/31/2019 | 81 | 24 | 34 | 35 | N/A |
12/31/2018 | 7 | -51 | -46 | -44 | N/A |
9/30/2018 | 22 | -32 | -28 | -26 | N/A |
6/30/2018 | 21 | -27 | N/A | -22 | N/A |
3/31/2018 | 20 | -29 | N/A | -24 | N/A |
12/31/2017 | 20 | -26 | N/A | -22 | N/A |
9/30/2017 | 5 | -35 | N/A | -35 | N/A |
6/30/2017 | 6 | -36 | N/A | -19 | N/A |
3/31/2017 | 25 | -10 | N/A | -10 | N/A |
12/31/2016 | 23 | -7 | N/A | -6 | N/A |
9/30/2016 | 22 | -8 | N/A | -4 | N/A |
6/30/2016 | 45 | 21 | N/A | 21 | N/A |
3/31/2016 | 39 | 17 | N/A | 16 | N/A |
12/31/2015 | 39 | 20 | N/A | 44 | N/A |
9/30/2015 | 65 | 46 | N/A | 45 | N/A |
6/30/2015 | 41 | 21 | N/A | 8 | N/A |
3/31/2015 | 28 | 10 | N/A | 7 | N/A |
12/31/2014 | 30 | 11 | N/A | -18 | N/A |
12/31/2013 | 9 | -11 | N/A | -20 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: Er wordt voorspeld dat ACIU de komende 3 jaar winstgevend zal worden, wat wordt beschouwd als een snellere groei dan de spaarquote ( 2.6% ).
Winst versus markt: Er wordt verwacht dat ACIU de komende 3 jaar winstgevend zal worden. Dit wordt gezien als een groei die boven het gemiddelde van de markt ligt.
Hoge groeiwinsten: Er wordt verwacht dat ACIU binnen 3 jaar winstgevend zal worden.
Omzet versus markt: De omzet van ACIU ( 32% per jaar) zal naar verwachting sneller groeien dan de markt US ( 8.9% per jaar).
Hoge groei-inkomsten: De omzet van ACIU ( 32% per jaar) zal naar verwachting sneller groeien dan 20% per jaar.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van ACIU naar verwachting over 3 jaar hoog zal zijn